Glycemic Control
Conditions
Keywords
Diabetes
Brief summary
This study seeks to determine whether varying the dose of insulin and glucose in diabetic patients during coronary bypass surgery will improve outcomes in these patients.
Detailed description
Our previous study has shown that maintaining serum glucose between 120-180mg/dl in the perioperative period during CABG surgery in diabetic patients improves outcomes. The purpose of this trial is: (1) to determine whether outcomes can be improved by altering the content of glucose or insulin in these solutions (2)to determine the effect of these solutions and glycemic control on the inflammatory response of arterial and venous conduits used during surgery, (3) to determine whether the beneficial effects of improved glycemic control can be correlated with changes in the inflammatory response.
Interventions
DRUGA IV Insulin drip
These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
DRUGB Low Dose GIK
These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
DRUGC High Dose GIK
This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
Sponsors
American Heart Association
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Diabetic CABG patients
Exclusion criteria
* Renal and hepatic failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| glycemic control, postoperative morbidity, inflammatory markers | 24 hours following surgery |
| glycemic control | 24 hours following surgery |
Secondary
| Measure | Time frame |
|---|---|
| free fatty acid levels | 24 hours following surgery |
Countries
United States
Outcome results
None listed